Mereo Biopharma Stock Price, News & Analysis

Mereo BioPharma Group plc (NASDAQ: MREO) announced promising clinical data from the ACTIVATE Phase 1b/2 study evaluating etigilimab, an anti-TIGIT antibody, combined with nivolumab for treating advanced solid tumors. The study observed continued clinical benefits, particularly in PD-L1 negative or low subjects, with significant complete responses in cervical cancer and other tumor types. Biomarker analysis indicates the potential of PVR, CD226, and TIGIT as predictive markers for patient enrichment. The trial is currently paused for further enrollment, with 30 patients remaining on study.

Mereo BioPharma Group plc (NASDAQ: MREO), a clinical-stage biopharmaceutical company, responded to Rubric Capital Management's requisition for a General Meeting of Shareholders aimed at removing four directors. In a letter dated August 22, 2022, Mereo highlighted deficiencies in Rubric's notice, asserting it did not meet the Companies Act 2006 requirements. Mereo indicated a willingness to engage with Rubric to resolve these issues, emphasizing that shareholders need not take any action at this time. The company aims to correct the noted deficiencies while maintaining shareholder relations.

Mereo BioPharma Group plc (NASDAQ: MREO) has regained compliance with Nasdaq's minimum bid price requirement. Following a notification on May 26, 2022, regarding non-compliance due to a closing bid price below $1.00 for 30 consecutive days, the company has successfully maintained a closing bid price of $1.00 or more for 10 consecutive business days, from June 17 to July 1, 2022. This achievement closes the matter with Nasdaq. Mereo focuses on innovative therapies for rare diseases and oncology, with products in clinical stages and significant partnerships.

Mereo BioPharma Group plc (NASDAQ: MREO) announced updated clinical results from its Phase 1b/2 Study of Etigilimab and Nivolumab in patients with advanced solid tumors (ACTIVATE). The data, to be presented at the ASCO Annual Meeting on June 5, 2022, shows 2 complete responses, 4 partial responses, and 10 stable diseases among 38 evaluable subjects, indicating a 15.8% overall response rate. The combination therapy was deemed safe with no new safety signals. Additionally, Mereo's capital allocation strategy has extended its cash runway to late 2024, positioning for further development in key programs.

Mereo BioPharma Group (NASDAQ: MREO) announced interim results from its Phase 1b/2 ACTIVATE study of Etigilimab and Nivolumab for solid tumors. As of February 10, 2022, results showed 1 Complete Response (CR), 2 Partial Responses (PR), and 9 Stable Diseases (SD) among 27 evaluated subjects, yielding an overall response rate (ORR) of 11% and a disease control rate (DCR) of 44%. The combination treatment was found safe with no new safety signals. Further data will be presented at ASCO 2022 on June 5, 2022.

Mereo BioPharma Group (NASDAQ: MREO) received a notification from Nasdaq on May 23, 2022, stating its American Depositary Shares (ADSs) did not meet the minimum bid price of $1.00 for 30 consecutive business days. This letter does not lead to immediate delisting, allowing trading to continue. Mereo has a 180-day compliance period, until November 21, 2022, to regain compliance. Failure to do so may result in a second grace period or delisting. The company intends to monitor its ADSs, and this notification does not affect its operations.

Mereo BioPharma Group plc (NASDAQ: MREO) announced the appointment of Dr. Abdul Mullick to its Board of Directors, effective immediately. Dr. Mullick brings over 20 years of pharmaceutical industry experience, including leadership roles in rare diseases. His expertise includes successfully launching two rare disease products in Europe. CEO Dr. Denise Scots-Knight expressed enthusiasm for Dr. Mullick's contributions during this pivotal phase for the company. Mereo focuses on developing innovative therapeutics for oncology and rare diseases, with several programs underway.

Mereo BioPharma (NASDAQ: MREO) announced positive results from the Phase 2 ASTRAEUS study of alvelestat, an oral neutrophil elastase inhibitor for severe alpha-1 antitrypsin deficiency-related emphysema. The study demonstrated statistically significant inhibition of blood neutrophil elastase activity by up to 90% across both high and low dose groups, alongside significant reductions in key biomarkers Aα-val³⁶⁰ and desmosine. Importantly, no safety signals were observed. Mereo plans further analysis and engagement with regulators for a pivotal trial design.

Mereo BioPharma Group plc (NASDAQ: MREO) will host a conference call on May 9, 2022, at 10:30 a.m. ET to discuss top-line clinical data from its ASTRAEUS Phase 2 Study of Alvelestat, targeting Alpha-1 Antitrypsin Deficiency-associated Emphysema. The call will be accessible via the Company's website and will remain archived for 14 days. Mereo's Alvelestat has received U.S. Orphan Drug Designation and is currently under investigation in a Phase 2 study with results expected in early Q2 2022.